Technical Analysis for CHRS - Coherus BioSciences, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 50 DMA Resistance | Bearish | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| 50 DMA Resistance | Bearish | -0.89% | |
| NR7 | Range Contraction | -0.89% | |
| Weak + Overbought | Other | -0.89% | |
| Inside Day | Range Contraction | -0.89% | |
| Weak, Overbought and Reversal Signs | Reversal | -0.89% | |
| Overbought Stochastic | Strength | -0.89% | |
| 50 DMA Resistance | Bearish | 0.45% |
| Alert | Time |
|---|---|
| Down 3% | about 10 hours ago |
| Outside Day | about 11 hours ago |
| Fell Below Previous Day's Low | about 11 hours ago |
| 60 Minute Opening Range Breakdown | about 12 hours ago |
| Down 2 % | about 12 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/09/2024
Coherus BioSciences, Inc. Description
Coherus Biosciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. Its clinical stage pipeline consists of CHS-0214, an etanercept biosimilar candidate, which is in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420, an adalimumab biosimilar candidate that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701, a pegfilgrastim biosimilar candidate, which has completed a Phase I study for the treatment of breast cancer patients exhibiting chemotherapy-induced neutropenia. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Immunology Breast Cancer Chemotherapy Treatment Of Breast Cancer Rheumatoid Arthritis Psoriasis Immunosuppressants Biosimilar Recombinant Proteins Adalimumab Neutropenia
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 5.91 |
| 52 Week Low | 1.435 |
| Average Volume | 2,219,523 |
| 200-Day Moving Average | 3.02 |
| 50-Day Moving Average | 2.26 |
| 20-Day Moving Average | 2.14 |
| 10-Day Moving Average | 2.12 |
| Average True Range | 0.15 |
| RSI (14) | 51.69 |
| ADX | 11.21 |
| +DI | 22.89 |
| -DI | 19.80 |
| Chandelier Exit (Long, 3 ATRs) | 2.17 |
| Chandelier Exit (Short, 3 ATRs) | 2.35 |
| Upper Bollinger Bands | 2.37 |
| Lower Bollinger Band | 1.91 |
| Percent B (%b) | 0.7 |
| BandWidth | 21.69 |
| MACD Line | -0.03 |
| MACD Signal Line | -0.06 |
| MACD Histogram | 0.0286 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.38 | ||||
| Resistance 3 (R3) | 2.38 | 2.33 | 2.36 | ||
| Resistance 2 (R2) | 2.33 | 2.29 | 2.33 | 2.35 | |
| Resistance 1 (R1) | 2.28 | 2.27 | 2.26 | 2.28 | 2.34 |
| Pivot Point | 2.23 | 2.23 | 2.22 | 2.23 | 2.23 |
| Support 1 (S1) | 2.18 | 2.19 | 2.16 | 2.18 | 2.12 |
| Support 2 (S2) | 2.13 | 2.17 | 2.13 | 2.11 | |
| Support 3 (S3) | 2.08 | 2.13 | 2.11 | ||
| Support 4 (S4) | 2.08 |
